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g.2013.0Abstract Helicobacter pylori (H. pylori) is currently recognized as one of the most common
chronic bacterial infections worldwide. Eradication of bacteria is effective in healing peptic ulcers,
preventing ulcer relapses, and potentially decreasing the risk of progression to gastric carcinoma.
For successful eradication of bacteria, it is imperative that the clinician be aware of the current anti-
microbial susceptibility proﬁles of isolates within the region. Therefore, the aim of this study is to
compare the phenotypic and genotypic patterns of antibiotics’ susceptibility to H. pylori strains
among Egyptian patients.
60 symptomatic cases were enrolled. H. pylori infection was diagnosed by upper endoscopy as
well as biopsy. Antimicrobial susceptibility to H. pylori strains was assessed in all subjects by disc
diffusion and Ellipsometer testing (E-testing) methods. Further molecular characterization of genesical Micrbiology & Immunol-
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236 M.S. Fathi et al.encoding antimicrobial resistance of isolated strains was done by the polymerase chain reaction
(PCR).
For metronidazole and ciproﬂoxacin, we compared the phenotypic and genotypic patterns of
resistance as detected by PCR ampliﬁcation of the resistance genes. Resistance rates by E-test were
100% and 25% for metronidazole and ciproﬂoxacin respectively from 16 isolated H. pylori strains.
Improving the knowledge of resistance mechanisms, the elaboration of rational and efﬁcacious
associations for the treatment H. pylori infection are of high importance especially in determining
the therapeutic outcome. Further progress should ultimately focus on the establishment of a cheap,
feasible and reliable laboratory test to predict the outcome of a therapeutic scheme.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Helicobacter pylori (H. pylori) infection, which affects half of
the world’s population, is responsible for gastritis [1], peptic ul-
cers [2,3] and gastric mucosa-associated lymphoid tissue lym-
phoma [4], and is a major risk factor for the development of
gastric adenocarcinoma [5]. Eradication treatment of H. pylori
infection usually consists of various combinations of drugs.
Most commonly, an acid suppressor (usually a proton pump
inhibitor) or a histamine receptor (H2-receptor) antagonist
(e.g. ranitidine) is prescribed in combination with two antibiot-
ics usually amoxicillin, metronidazole or clarithromycin. The
combination of two antibiotics can increase the success of
eradication therapy and decrease the possibility of secondary
antibiotic resistance [6,7].
Antibiotic resistance in H. pylori is the major cause of erad-
ication failure. Growing resistance often parallels the patterns
of antibiotic consumption, and may vary within patient groups
according to the geographic region, patient age and sex, type
of disease, birthplace and the presence of other infections.
The geographic map and the process of primaryH. pylori resis-
tance are clinically important, and should be considered when
choosing eradication regimens, as is constant monitoring at
both national and global level in an attempt to reach the re-
cently recommended goal of eradicating more than 95% of
resistant cases [8]. Different mechanisms of resistance to clari-
thromycin, metronidazole, quinolones, amoxicillin and tetra-
cycline are accurately detailed (point mutations, redox
intracellular potential, pump efﬂux systems, membrane perme-
ability) on the basis of the most recent data available from the
literature [9].
The prevalence of clarithromycin, metronidazole and
amoxicillin resistance varies between countries and is highest
for metronidazole [10]. Resistance to tetracycline and cipro-
ﬂoxacin has been reported by several studies but yet appears
uncommon [11,12].
The activation of metronidazole is mediated by the pyru-
vate: ferredoxin oxidoreductase complex. For example, this
function in H. pylori might be fulﬁlled by the electron carriers,
RdxA (HP0954), an oxygen-insensitive NADPH nitroreduc-
tase, FrxA (HP0642), a NAD(P)H-ﬂavin oxidoreductase, fer-
redoxin (FdxA, HP0277), ﬂavodoxin (FldA, HP1161),
pyruvate: ferredoxin oxidoreductase (PorD, HP1109) and 2-
oxoglutarate ferredoxin oxidoreductase (OorD, HP0588).
Inactivation of the genes involved in some of these systems
has been found to be linked to metronidazole resistance [13].
There are several problems with antimicrobial susceptibility
testing of H. pylori [14,15]. Agar or broth dilution methods aredifﬁcult to perform routinely [16], thus, disc diffusion testing is
often used because it is simple, easy to perform, and econom-
ical [17]. However, the E-test has proved to be an accurate
method for assaying the susceptibility of fastidious organisms,
including H. pylori, to antibiotics. The E-test has a more stable
pattern of antibiotic release and has been found to tolerate
prolonged incubation [18]. This is the main reason why the
E-test rather than the disc diffusion method, has been recom-
mended for H. pylori [19].
With the increasing frequency of clarithromycin resistance
among H. pylori strains, there is rising concern about the po-
tential decline in the eradication rate of this infection [20,21].
There is therefore an urgent need to introduce other treatment
options. Fluoroquinolones, such as ciproﬂoxacin (CIP), levo-
ﬂoxacin (LVX) and moxiﬂoxacin (MOX), have been evaluated
as an alternative to standard antibiotics against H. pylori [6,7].
Some studies have shown good results when using ﬂuoro-
quinolone based triple therapies for H. pylori eradication. In
a German study, a 7 day course including LVX in patients
with persistent H. pylori infection resulted in eradication rates
of greater than 85% [22]. Similarly, an Italian study clariﬁed
that H. pylori eradication was achieved in 90% of patients
treated with MOX, clarithromycin and lansoprazole [23].
However, the widespread use of ﬂuoroquinolones for the treat-
ment of H. pylori infection has led to an increase in its resis-
tance rate in some areas, leading to unacceptably low
eradication rates [10]. Several studies have shown that LVX
based therapies are not superior to the traditional quadruple
therapy or triple therapy in the treatment of H. pylori infec-
tion, especially in the case of resistant H. pylori strains [24,25].
On the other hand a Turkish study speculated that the low
eradication rate with MOX containing treatment regimens
may be due to the development of resistance to this quinolone
[26]. The ﬁndings from all of these studies indicate that a reg-
imen that is effective in one area may not be effective in an-
other area, as antibiotic resistant rates for H. pylori may be
different in different areas [27].
The mechanism of action of ﬂuoroquinolones is via inhibi-
tion of deoxyribonucleic acid (DNA) gyrase and topoisomer-
ase, which control and modify the topological state of DNA
in cells. Fluoroquinolone then interferes with bacterial DNA
replication. Both DNA gyrase and topoisomerase are com-
posed of two A and two B subunits, encoded by the gyrA
and gyrB genes for DNA gyrase and the parC and parE genes
for topoisomerase. The mechanism of ﬂuoroquinolone resis-
tance in H. pylori has been found to be linked to mutations
in the quinolone resistance determining regions (QRDRs) of
the gyrA gene. Mutations in the gyrB gene have also been re-
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ten occurred along with gyrA mutations [8].
In vitro susceptibility testing for H. pylori can be performed
either by phenotypic or genotypic methods. Phenotypic testing
is challenging because the organism grows slowly even under
optimal culture conditions. Owing to these difﬁculties and be-
cause antibiotic resistance in this microorganism is essentially
due to point mutations, genotypic methods are an alternative
to the phenotypic methods. Moreover, these methods offer
the advantage of testing directly from biopsy material, allow-
ing a faster response.
2. Aim of the study
The aim of this study is to compare the phenotypic and geno-
typic patterns of antibiotics’ susceptibility to H. pylori strains
among Egyptian patients in order to attain a clinical utility
from such patterns.
3. Subjects and methods
3.1. Study design and sampling
This cross-sectional study was conducted on 60 cases with epigas-
tric pain and/or vomiting attended to the outpatient clinics and/or
the endoscopy centre of AhmedMaherHospital during the period
fromMay2011 to January 2012.The sample sizewas calculated by
Epi Info program (version 6.0) at 95%ConﬁdenceLimit, Power of
the Test is 80% and Alpha Set at 0.05 (Type I error).
3.1.1. Inclusion criterion
Patients with epigastric pain and/or vomiting.
3.1.2. Exclusion criteria
Patients who refused to be enrolled in the study, patients who
previously underwent sclerotherapy or band ligation of
oesophageal varices (EV), patients taking drugs for primary
prophylaxis of variceal bleeding, patients with chronic liver
disease and/or hepatocellular carcinoma, patients with portal,
splenic or hepatic vein thrombosis and patients with severe car-
diac, chest or renal disease.
3.2. Tools of the study
All patients were subjected to a complete clinical evaluation and
laboratory investigations: including: complete blood count
(CBC), liver proﬁle and hepatitis markers: Hepatitis B surface
antigen (HBs Ag) and Hepatitis C virus antibody (HCV Ab)
using the third generation enzyme-linked immunosorbent assay
(ELISA) test (Franciscus, 2002 and[29]). Abdominal ultrasonog-
raphy was done using Toshiba ‘‘Just vision’’ real-time scanner
instrument with a 3.5 MHz convex transducer (after an over-
night fasting) with stress on: liver size and liver echogenicity.
Upper gastrointestinal (GI) endoscopy and endoscopic guided
biopsy were done to exclude the presence of varices in addition
to any relevant upper GI masses and to evaluate the degree of
gastritis or the presence of ulcers using Pentax EG-3440 video-
scope system. The endoscopic study was performed by the same
examiner in all patients to avoid interobserver variability [30].
Gastric biopsies were collected on phosphate buffered saline(PBS) in sterile eppendorf tubes. Some patients had received
H. pylori eradication therapy before, but none of the patients
had received MOX or CIP based therapy [30].
3.3. Identiﬁcation and storage of H. pylori strains
The biopsy specimens were cultured on Colombia blood agar
(BBL Microbiology Systems, Cockeysville, MD, USA), sup-
plemented with 8% deﬁbrinated sheep blood, and incubated
for 5–7 days under microaerobic conditions (5% O2, 10%
CO2, 85% N2) [30].
Clinical isolates were identiﬁed as H. pylori based on mor-
phology and positive biochemical tests for catalase, oxidase,
and conﬁrmed by the rapid urease production test and gram
staining.
Sixteen pure isolates were identiﬁed as H. pylori. They were
stored at 80 C in brain–heart infusion broth (BHI, Difco
Laboratory, Detroit, MI, USA) supplemented with 30%
glycerol.
3.4. Antimicrobial susceptibility to H. pylori strains
3.4.1. Antimicrobial susceptibility testing by disc diffusion
method
For in vitro susceptibility testing of the H. pylori strains, a sus-
pension equal to the McFarland tube No. 3 was prepared for
each isolate. We used only one colony from each isolate for the
analysis. Brain heart infusion broth (Merck, Germany) plates,
supplemented with sheep red blood cells (RBCs) were inocu-
lated by conﬂuent swabbing of the surface with the adjusted
inoculum suspensions.
The antimicrobial discs (Mast Diagnostics; Mast Group
Limited, Mereyside, UK) for the antibiotics amoxicillin, met-
ronidazole, tetracycline, ciproﬂoxacin, and clarithromycin,
were aseptically placed onto the dried surface of inoculated
Muller Hinton’s agar plates supplemented with sheep RBCs.
The plates were then incubated at 37 C under microaerobic
conditions [31]. The zones of inhibition were read after 24–
48 h of incubation and the susceptibility results were recorded
as resistant on the basis of the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines and the manufacturer’s
instructions [28,31].
3.4.2. Determination of the minimum inhibitory concentrations
(MIC)
The E-test strips (Lioﬁlchem, Italy) for the antibiotics amoxi-
cillin, metronidazole, tetracycline, ciproﬂoxacin, and clarithro-
mycin were aseptically placed onto the dried surface of
inoculated agar plates. The plates were then incubated at
37 C under microaerobic conditions. The minimum inhibitory
concentrations (MICs) were read after 48–72 h of incubation
on the basis of the intersection of the elliptical zone of growth
inhibition using the MIC scale on the E-test strip, and the sus-
ceptibility results were recorded as resistant according to the
recommendations of CLSI (Pennsylvania, USA) and the man-
ufacturer’s instructions [28,31].
A polymerase chain reaction (PCR) was performed for the
16 isolates to detect Ure C gene (a 1335 base pair (bp) long
open reading frame upstream from the urease structural genes
(ureAB) of H. pylori whose product is important for cell
growth) for conﬁrmation of the identiﬁcation of H pylori. An-
Table 1 Descriptive data of positive ﬁndings of the studied cases.
Variables Studied cases no. = 60
No. %
Age (years) Mean ± SD 46.7 ± 8.8
Range 5.0–60.0
Sex Female 22 36.7%
Male 38 63.3%
HCV-Antibodies 18 30.0%
Clinical symptoms and signs Nausea 22 36.7%
Haematemesis 6 10.0%
Abdominal distension 22 36.7%
Epigastric pain 52 86.7%
Laboratory investigations Complete blood count Haemoglobin 11.9 ± 1.9
WBCs 4.8 ± 1.5
Platelets 178.0 ± 26.0
Liver enzymes ALT 29.7 ± 29.1
AST 36.9 ± 31.9
Abdominal ultrasound Liver size Average 46 76.7%
Enlarged 14 23.3%
Liver echogenicity Coarse 12 20.0%
Bright 12 20.0%
Homogenous 24 40.0%
Diﬀuse 12 20.0%
Upper endoscopy Duodenitis 28 46.7%
Antral erosions 26 43.3%
Both 6 10.0%
Grading Grade 0 42 70.0%
Grade I 4 6.7%
Grade II 10 16.7%
Grade III 4 6.7%
Culture Positive 16 26.7%
Negative 44 73.3%
Antibiotic disc diﬀusion
sensitivity test
Tetracycline Sensitive 6 37.5%
Resistant 10 62.5%
Clarithromycin Sensitive 0 0%
Resistant 16 100.0%
Metronidazole Sensitive 0 0%
Resistant 16 100.0%
Ciproﬂoxacin Sensitive 14 87.5%
Resistant 2 12.5%
Amoxycillin Sensitive 2 12.5%
Resistant 14 87.5%
E-test Clarithromycin Intermediate 8 50.0%
Resistant 8 50.0%
Metronidazole Sensitive 0 0%
Resistant 16 100.0%
Cirproﬂoxacin Sensitive 12 75%
Resistant 4 25%
Amoxycillin Resistant 16 100%
Tetracycline Sensitive 4 25%
Resistant 12 75%
PCR gyrA and gyrB genes Present 16 100.0%
Rdx gene Present 12 75.0%
Absent 4 25.0%
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tion of the DNA gyrase (gyrA and gyrB) genes responsible for
resistance to ﬂuoroquinolones and also the rdx gene responsi-
ble for the resistance to metronidazole.
3.5. Polymerase chain reaction (PCR) procedure
3.5.1. Extraction of DNA
1.5 ml of broth culture of each isolate was taken for extraction
of DNA. Extraction was performed using QIAamp DNA
MINI KIT (QIAGEN, USA) (Catalog No. 51304) according
to the manufacturer’s instructions.3.5.2. Ampliﬁcation of the extracted DNA
Ampliﬁcation of the eluted DNAwas performed in a 50 ll reac-
tion volume for each of the four detected genes. Each PCR mix
consisted of 25 ll of 2x QIAGEN HotStar Taq Master Mix
Containing HotStarTaq DNA Polymerase, PCR buffer (with
3 mM MgCl2), and 400 lM each dNTP + 10 ll of the eluted
DNA+ 1 ll of each of the 2 primers (50 pM) of the gene to
be detected + 13 ll distilled water.
Primers were synthesized by (Roche, Germany).
Ampliﬁcation of DNA was performed in a thermal cycler
(thermo PxE 0.21, England).Table 2 Comparative assessment between culture positive and cult
Variables Culture
Age Mean ± SD 50.9 ±
Sex Male 10 (62.
Female 6 (37.5
HCV-antibodies 2 (12.5
Clinical symptoms and signs Nausea 6 (37.p
Haematemesis 0 (.0%
Abdominal distension 8 (50.0
Epigastric pain 14 (87.
Abdominal US Liver size Average 12 (75.
Enlarged 4 (25.0
Liver echo Coarse 0 (.0%
Bright 4 (25.0
Homogenous 8 (50.0
Diﬀuse 4 (25.0
Upper endoscopy Duodenitis 6 (37.5
Antral erosions 8 (50.0
Both 2 (12.5
Grading Grade 0 0 (0.0%
Grade I 2 (12.5
Grade II 10 (62.
Grade III 4 (25.0
NS: Non signiﬁcant.
S: Signiﬁcant.
HS: Highly signiﬁcant.
* Chi square test.
** Fisher’s exact test.
 Student’s t test.3.5.3. Detection of the ureC gene
It was detected in the reaction mix described above using the
following primers [38]:
50-AAGCTTTTAGGGGTGTTAGGGGTTT-30 and R 50-
AAGCTTATTTCTAACGC-30. Thermocycling conditions
were 35 cycles at 94 C for 1 min, 55 C for 1 min, and 72 C
for 1 min, with a ﬁnal extension step of 72 C for 10 min.,
which ampliﬁes a 295-bp amplicon.
3.5.4. Detection of the rdxA gene
It was detected in the reaction mix described above using the
following primers [38]:
rdxA1 (50-AATTTGAGCATGGGGCGA-30) and rdxA2
(50-AAACGCTTGAAAACACCCT-30)
Thermocycling conditions were 35 cycles at 94 C for 1 min,
55 C for 1 min, and 72 C for 1 min, with a ﬁnal extension
step of 72 C for 10 min., which ampliﬁes a 851-bp amplicon.
3.5.5. Detection of the gyrA and gyrB genes
It was detected in the reaction mix described above using the
following primers [8]:
Gyr APF (50-AGCTTATTCCATGAGCGTGA-30) and gyr
APR (50-TCAGGCCCTTTGACAAATTC-30), gyrBPF (50-
CCCTAACGAAGCCAAAATCA-30) and gyr BPR (50-
GGGCGCAAATAACGATAGAA-30) that were designed to
amplify a 582 bp and 465 bp amplicons, respectively.ure negative by upper endoscopy.
positive no. = 16 Culture negative no = 44 P Sig.
7.5 45.2 ± 8.9 .027 S
5%) 28 (63.6%) .936* NS
%) 16 (36.4%)
%) 16 (36.4%) .112** NS
5%) 16 (36.4%) .936* NS
) 6 (13.6%) .179** NS
%) 14 (31.8%) .196* NS
5%) 38 (86.4%) 1.00** NS
0%) 34 (77.3%) 1.00** NS
%) 10 (22.7%)
) 12 (27.3%) .098** NS
%) 8 (18.2%)
%) 16 (36.4)
%) 8 (18.2%)
%) 22 (50.0%) .630** NS
%) 18 (40.9%)
%) 4 (9.1%)
) 42 (95.5%) .0001** HS
%) 2 (4.5%)
5%) 0 (0.0%)
%) 0 (0.0%)
240 M.S. Fathi et al.Thermocycling conditions were 35 cycles at 94 C for 1 min,
53 C for 1 min, and 72 C for 1 min, with a ﬁnal extension
step of 72 C for 10 min.
Identiﬁcation of ampliﬁed products by gel electrophoresis
was done as the following [32]:
The amplicons (2 ll) (added to a Loading buffer: bromo-
phenol blue with sucrose) was analysed by electrophoresis on
2% agarose gel and ethidium bromide staining in tris–ace-
tate-EDTA (TAE) running buffer. They were visualized on a
UV transilluminator (365 wave length). Qiagen gel pilot 1 Kb
plus. (cat No. 239045) was used as molecular weight ladder.
3.5.6. Data management and statistical analysis
The collected data were revised, coded, tabulated and intro-
duced to a PC using Statistical package for Social Science
(SPSS 15.0.1 for windows; SPSS Inc, Chicago, IL, 2001). Quan-
titative non parametric variables are expressed as mean and
standard deviation (SD), while non parametric were expressed
as Median and Interquartile range (IQR). Qualitative variablesTable 3 Comparative assessment between different endoscopic ﬁnd
Variables Duodeniti
Age Mean ± SD 46.07 ± 8.
Sex Male 14 (50.0%
Female 14 (50.0%
Clinical symptoms and signs Nausea 10 (35.7%
Haematemesis 6 (21.4%)
Abdominal distension 8 (28.6%)
Epigastric pain 26 (92.9%
Grading Grade 0 22 (78.6%
Grade I 0.0%
Grade II 621.4%
Grade III 0.0%
Culture Positive 6 2(1.4%)
Negative 22 (78.6%
Disc diﬀusion Tetracycline Sensitive 4 (66.7%)
Resistant 2 (33.3%)
Clarithromycin Resistant 6 (100.0%
Metronidazole Resistant 6 100.0%)
Ciproﬂoxacin Sensitive 6 (100.0%
Resistant 0 (.0%)
Amoxycillin Sensitive 0 (.0%)
Resistant 6 (100.0%
E-test Clarithromycin Intermediate 4 (66.7%)
Resistant 2 (33.3%)
Metronidazole Resistant 6 (100.0%
Ciproﬂoxacin Sensitive 2(50%)
Resistant 6 (50%)
Amoxycillin Resistant 8 (100%)
Tetracycline Resistant 6 (100%)
Sensitive 2 (50%)
PCR Ciproﬂoxacin Present 6 (100.0%
Metronidazole Present 4 (66.7%)
Absent 2 (33.3%)
NS: Non signiﬁcant
S: Signiﬁcant
HS: Highly signiﬁcant
* ANOVA.
** Fisher’s exact test; NA.are expressed as frequencies and percents. Student’s t test and
ANOVA test were used to compare a continuous variable be-
tween two and more than two study groups respectively. Chi
square and Fisher’s exact test were used to examine the rela-
tionship between categorical variables. Marginal homogeneity
test was used to assess the statistical signiﬁcance of the differ-
ence of a variable with multiple categories measured by two dif-
ferent methods for the same study group. P-value: level of
signiﬁcance (P> 0.05: Non signiﬁcant (NS), P< 0.05: Signif-
icant (S) and P< 0.01: Highly signiﬁcant (HS)).
4. Results
A total of 16 H. pylori strains were isolated from 60 patients
included in this study, 10(62.5%) from males and 6(37.5%)
from females. The demographic, clinical, laboratory, endo-
scopic examination and antibiotic sensitivity data of the 60 pa-
tients enrolled in the study are presented in Table 1. Thirty-
eight of the cases were males (63.3%), the mean ± SD ofings.
s no. = 28 Antral erosions no. = 26 Both no. = 6 P Sig.
205 49.38 ± 7.803 38.33 ± 11.255 .016* S
) 18 (69.2%) 6 (100.0%) .055** NS
) 8 (30.8%) 0 (.0%)
) 12 (46.2%) 0 (0.0%) .100** NS
0 (0.0%) 0 (.0%) .033** S
10 (38.5%) 4 (66.7%) .242** NS
) 20 (76.9%) 6 (100.0%) .187** NS
) 16 (61.5%) 4 (66.7%) .028** S
4 (15.4%) 0 (.0%)
4 (15.4%) 0 (.0%)
2 (7.7%) 2 (33.3%)
8 (30.8%) 2 (33.3%) .630** NS
) 18 (69.2%) 4 (66.7%)
0 (.0%) 2 (100.0%) .003** HS
8 (100.0%) 0 (.0%)
) 8 (100.0%) 2 (100.0%) . . .. . .. . . ...
8 (100.0%) 2 (100.0%) . . ... . . ...
) 6 (75.0%) 2 (100.0%) .600** NS
2 (25.0%) 0 (.0%)
2 (25.0%) 0 (.0%) .600** NS
) 6 (75.0%) 2 (100.0%)
4 (50.0%) 0 (.0%) .347** NS
4 (50.0%) 2 (100.0%)
) 8 (100.0%) 2 (100.0%) . . .. . .. . . ...
0(0%) 2 (50%)
6 (50%) 0(0%) NS
4 (100%) 4 (100%) NS
3(100%) 3 (100%) NS
2 (50%) ———— NS
) 8 (100.0%) 2 (100.0%) . . .. . .. . . ...
6 (75.0%) 2 (100.0%) 1.00** NS
2 (25.0%) 0 (.0%)
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tive HCV-Antibodies, epigastric pain was the main clinical
presentation of the enrolled cases (86.7%). Upper endoscopy
revealed duodenitis, antral erosions or both (46.7%, 43.3%,
and 10.0%, respectively), 70% was grade 0 of the pathological
examination, 73.3% was culture negative. We also compared
between culture positive and culture negative by upper endoscopy
(Table 2). Table 3 shows a comparative assessment between dif-
ferent endoscopic ﬁndings. Table 4 shows a comparative assess-
ment between different pathological grades.
Regarding antibiotic disc diffusion sensitivity test, the sen-
sitivity was 37.5% in tetracycline 100.0% in clarithromycin,
0% in Metronidazole, 87.5% in Ciproﬂoxacin, 12.5% in
Amoxycillin. While concerning E-test, Clarithromycin was
intermediate in 50.0%, the sensitivity in Metronidazole was
0%, Cirproﬂoxacin in 75%, Tetracycline in 25%. Table 5
shows a non- signiﬁcant difference between males and females
regarding the resistance rates to all the tested antibiotics either
by disc diffusion, E-test or the results of PCR.
For molecular characterization of our strains, we ﬁrstly
conﬁrmed the presence of bacterial DNA of H pylori by ampli-
fying the Ure C gene (a house keeping gene) (Fig. 1) by PCR.
Then, secondly, we investigated the presence of resistance
genes of Fluoroquinolones (gyrA and gyrB genes) which were
found in 100% of isolates (Fig. 3) and Metronidazole (rdx
gene) which was found in 75.0% (Fig. 2). Furthermore our re-
sults revealed an agreement between results of antimicrobial
susceptibility testing by disc diffusion and E testing of (A)
Clarithromycin & (B) Metronidazole (Fig. 4).
The 16 tested isolates (100%) were resistant to metronida-
zole by E-testing. However the rdxA gene was detected in 12
isolates (75%). While 12 (75%) isolates were resistant to cipro-
ﬂoxacin by E-testing, with the gyrA and gyrB genes detected in
16 (100%) of isolates (Table 6).Table 4 Comparative assessment between different pathological gr
Variables Grade I no. = 2
N (%)
Disc diﬀusion Tetracycline Sensitive 0 (.0%)
Resistant 2 (100.0%)
Clarithromycin Resistant 2 (100.0%)
Metronidazole Resistant 2 (100.0%)
Ciproﬂoxacin Sensitive 0 (0%)
Resistant 2 (100.0%)
Amoxycillin Sensitive 0 (.0%)
Resistant 2 (100.0%)
E-test Clarithromycin Intermediate 0 (0%)
Resistant 2 (100.0%)
Metronidazole Resistant 2 (100.0%)
Ciproﬂoxacin Resistant 4 (25%)
Sensitive 0 (0%)
Amoxycillin Resistant 2 (100%)
Tetracycline Resistant 2 (100%)
Sensitive 0(0%)
PCR gyrA and gyrB Present 2 (100.0%)
Absent 0 (0%)
rdx gene Present 2 (100.0%)
NS: Non signiﬁcant.
HS: Highly signiﬁcant.
** Fisher’s exact test.5. Discussion
In the present study we evaluated the sensitivity of sixteen H.
pylori strains isolated from patients with gastric disorders to
ﬁve different antibiotics (metronidazole, tetracycline, clarithro-
mycin, amoxicillin and ciproﬂoxacin) using the disc diffusion
method. MIC determination for metronidazole and clarithro-
mycin was done by E-test to ﬁnd the resistance pattern in these
strains in our region.
For metronidazole and ciproﬂoxacin, we compared the
phenotypic and genotypic patterns of resistance as detected
by PCR ampliﬁcation of the rdxA, gyrA and gyrB genes.
In this work, the resistance rate to metronidazole detected
by E-test was 100% consistent with reports from developing
countries that described a high level of resistance to metronida-
zole, which varies from 66.2% to 100% [33,34]. However re-
ports from developed countries record lower rates of
resistance to metronidazole where it has been reported that
15.8% to 40% of H. pylori strains were resistant to metronida-
zole [35–37]. This discrepancy in resistance rates to metronida-
zole between developing and developed countries could be
attributed to the frequent use of the drug, which is commonly
prescribed for other diseases, especially parasitic conditions,
and periodontal or gynaecological infections. Moreover, the
use or abuse of this inexpensive drug may contribute to the in-
creased metronidazole resistance seen in developing countries.
As shown in Table 5 both male and female patients showed
100% resistance rates to metronidazole by E-test and a non
signiﬁcant difference in detection of resistance gene. This dis-
agrees with Farshad et al. [19] and Kargar et al. [38] who re-
ported a higher resistance rate in females that could be
attributed to the use of this drug for treatment of gynaecologic
infections. The non signiﬁcant difference we report may be dueades.
Grade II no. = 10 Grade III no. = 4 P Sig.
N (%) N (%)
4 (40.0%) 2 (50.0%) .610** NS
6 (60.0%) 2 (50.0%)
10 (100.0%) 4 (100.0%) ——— ——
10 (100.0%) 4 (100.0%) ——— ——
10 (100.0%) 4 (100.0%) .008** HS
0 (.0%) 0 (0%)
2 (20.0%) 0 (0%) 1.00** NS
8 (80.0%) 4 (100.0%)
6 (60.0%) 2 (50.0% .504** NS
4 (40.0%) 2 (50.0%)
10 (100.0%) 4 (100.0%) ——— ——
0 (0%) 0(0%) ———
10 (100%0 2 (50%)
10(100%) 4 (100%)
10(100%) 0 (0%)
4 (100%) 0 (0%)
10 (100.0% 4 (100.0%) ——— ——
4 (40.0%) 0 (0%)
6 (60.0%) 4 (100.0%) .258** NS
Table 5 Rates of antibiotic resistance in Helicobacter pylori isolates in relation to patient gender.
Variables Male no. = 10 Female no. = 6 no. = . . . P Sig.
N (%) N (%)
Disc diﬀusion Tetracycline Sensitive 2 (20.0%) 4 (66.7%) .118** NS
Resistant 8 (80.0%) 2 (33.3%)
Clarithromycin Resistant 10 (100.0%) 6 (100.0%) ——— ——
Metronidazole Resistant 10 (100.0%) 6 (100.0%) ——— ——
Ciproﬂoxacin Sensitive 8 (80.0%) 6 (100.0%) .500** NS
Resistant 2 (20.0%) 0 (.0%)
Amoxycillin Sensitive 0 (.0%) 2 (33.3%) .125** NS
Resistant 10 (100.0%) 4 (66.7%)
E-test Clarithromycin Intermediate 4 (40.0%) 4 (66.7%) .608** NS
Resistant 6 (60.0%) 2 (33.3%)
Metronidazole Resistant 10 (100.0%) 6 (100.0%) ——— ——
Ciproﬂoxacin Sensitive 5 (41%) 7(59%)
Resistant 2 (50%) 2(50%) NS
Amoxycillin Resistant 12 (100%) 4 (100%) NS
Tetracycline Resistant 6 (100%) 6(100%) NS
Sensitive 4(100%) 0(0%) NS
PCR Ciproﬂoxacin Present 10 (100.0%) 6 (100.0%) ——— ——
Metronidazole Present 8 (80.0%) 4 (66.7%) .604** NS
Absent 2 (20.0%) 2 (33.3%)
NS: Non signiﬁcant.
** Fisher’s exact test.
Table 6 Relationship between genotypic and E-test phenotypic pattern as regards sensitivity against metronidazole, relationship
between genotypic and disc diffusion phenotypic pattern as regards sensitivity against metronidazole and ciproﬂoxacin.
Variables rdx gene P Sig.
Present = 12 Absent = 4
N % N %
E-test Metronidazole * Sensitive 0 .0 0 .0 ——— ——
Intermediate 0 .0 0 .0
Resistant 12 100.0 4 100.0
** Sensitive 0 .0 0 .0 —— ———
Resistant 12 75.0 4 25.0
gyrA and gyrB genes
Ciproﬂoxacin *** Sensitive 12 75 0 .0 —— ———
Resistant 4 25 0 .0
242 M.S. Fathi et al.to the narrow sample size and restriction of sampling from pa-
tients who routinely are candidates for upper gastroscopy.
Metronidazole is administered as a pro-drug that is acti-
vated by the reduction of the nitro group that is attached to
an imidazole ring. Inactivation of an oxygen-insensitive
NADPH nitroreductase (rdxA) may be responsible for metro-
nidazole resistance. The activation of metronidazole in strictly
anaerobic bacteria is mediated by the pyruvate: ferredoxin oxi-
doreductase complex. For example, this function in H. pylori
might be fulﬁlled by the electron carriers, RdxA (HP0954),
FrxA (HP0642), ferredoxin (FdxA, HP0277), ﬂavodoxin
(FldA, HP1161), pyruvate: ferredoxin oxidoreductase (PorD,
HP1109) and 2-oxoglutarate ferredoxin oxidoreductase
(OorD, HP0588) [13].
In this study we investigated the rdxA gene deletion as a
factor of resistance to metronidazole. Table 4 shows that only25% of isolates were negative for rdxA gene by PCR, although
100% of cases were phenotypically resistant to metronidazole
by disc diffusion and E-test methods. This ﬁnding goes in
alignment with Abdollahi et al. [13] who reported a 22.9% rate
of rdxA gene deletion among their 35 tested resistant H. pylori
strains. These results can be explained by the presence of mech-
anisms of rdxA inactivation rather than deletion, for example
mutational inactivation which can be identiﬁed by further
sequencing of the ampliﬁed DNA. Another mechanism that
may be associated with rdxA gene inactivation is the insertion
of a transposon called Mini-IS605 [39]. It has also been dem-
onstrated that inactivation of other genes such as the frxA gene
also confers metronidazole resistance, either alone or in asso-
ciation with the rdxA gene [40,41].
The present study revealed a high resistance rate to amox-
icillin by E-test of 87.5% (Table 1). This rate agrees with
Figure 1 Gel electrophoresis showing PCR products (The ureC (glmM) gene 295-bp amplicon) fragment size measured against
GeneRuler 100 bp Plus DNA Ladder. Bands are seen in lanes from 1 to 13 (N.B three isolates were not photographed).
Figure 3 Gel electrophoresis showing PCR products (Fluoro-
quinolones resistance gene {gyr A: 582 bp, gyr B:465 bp})
fragment size measured against GeneRuler 100 bp Plus DNA
Ladder . Gyr A bands are shown in lanes 1,2 while Gyr B bands
are shown in lanes from 3 to 10.
Figure 2 Gel electrophoresis showing PCR products (Metronidazole resistance gene {Rdx: 600 bp}) fragment size measured against
GeneRuler 100 bp Plus DNA Ladder. Bands are seen in lanes 11 to 16.
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examined 32 isolates. In the same context, Okimoto and Mura-
kami [42]; Godoy et al. [43] and Kumala and Rani [44] re-
ported resistance rates to amoxicillin of 38%, 32.8% and
19.4%, respectively. In contrast to these rates, Boyanova
et al. [37]; Malfeltheiner et al. [6] and John Albert et al. [45] re-
ported that amoxicillin resistance was very rare or even non-
existing. This wide variation in amoxicillin resistance rates re-
ported from different countries could be attributed to the re-
gional prescribing practice of the drug.
Clarithromycin is utilized in the recommended ﬁrst line tri-
ple therapies against H. pylori. This study noticed a high resis-
tance rate to clarithromycin of 100% by the disc diffusion
method (Table 1), however only 50% (8 out of 16 isolates)
were conﬁrmed to be resistant to clarithromycin by E-test
(Table 1). This rate agrees with that of Abadi et al. [46] who
found that 45.2% of 197 H. pylori isolates are resistant to clar-
ithromycin by the disc diffusion method. Furthermore, Ilie
et al. [47] reported a resistance rate to clarithromycin of 32%
of their tested isolates. In contrast, the rate of clarithromycin
resistance reported in this study is much higher than that re-
ported by Milani et al. [48] who found a rate of resistance of
14.3% (16 out of 112 H. pylori isolates). Similarly, Boyanova
et al. [49] reported a lower rate of primary resistance to clai-
thromycin of 17.9% of 519 H pylori strains. The high rate ofclarithromycin resistance detected in this study is likely a con-
sequence of an overuse of macrolides for the treatment of
upper respiratory tract infections.
Figure 4 Agreement of results of antimicrobial susceptibility testing by disc diffusion & e Testing of (A) Clarithromycin & (B)
Metronidazole.
244 M.S. Fathi et al.Ciproﬂoxacin belongs to the ﬂuoroquinolone group of anti-
biotics that are generally used as part of rescue therapy for
treating H. pylori infections when ﬁrst and second line thera-
pies have failed [50]. Resistance to ﬂuoroquinolones is gener-
ally very low (<10%) worldwide [51]. In our study we found
a low resistance rate for ciproﬂoxacin using the disc diffusion
method (2 out of 16 isolates) 12.5% and 25% by E-testing (Ta-
bles 1 and 4) which matches with that detected by Boyanova
et al. [49] that was 10.8% of 519 isolates, and with that of
Chung et al. [52] who reported a resistance rate of 15.7% of
185 isolates detected by MIC. The rate reported in this study
is lower than that detected by Abadi et al. [46] and Milani
et al. [48] who reported resistance to ciproﬂoxacin in 34.5%
of 197 isolates and in 33% of isolates (37 out of 112 isolates),
respectively.
Further sequencing of the ampliﬁcation products of the
gyrA and gyrB genes should have been done for the detection
of the point mutations related to resistance to ciproﬂoxacin.
However, unfortunately it was not feasible to perform such
technique.
In this study we detected 10 resistant strains to tetracycline
out of the 16 tested isolates (62.5%) (Table 1), this rate is much
higher than most reports. For example, Chung et al. [52] found
only 1 resistant strain to tetracycline out of the 185 examined
strains (0.5%). In the same context, Boyanova et al. [49] re-
ported a rate of resistance of 4% for tetracycline. In the current
study, a non signiﬁcant difference was found between males
and females regarding tetracycline resistance, and this lodges
in controversy with Boyanova et al. [49] who allocated female
sex as the only predictor of primary tetracycline resistance.
6. Conclusion
The present study elucidated the primary state of H. pylori iso-
lates from Egyptian patients regarding their susceptibility to
currently used anti-microbial drugs. It brings attention to
establish a designed plan for antimicrobials prior to launching
of treatment in order to accomplish better integration between
microbiological assessment and clinical usage of antimicrobials
on a broad scale and regular basis. This could contribute to
further successful eradication of H. pylori, thus minimizing
the risk of chronicity and consequently malignant transforma-
tion and sequential complications.References
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